Historique
Périodique
Pilot-randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence
(Etude pilote randomisée en double aveugle, contre placebo, de l'efficacité de la dexamphétamine dans la dépendance à la cocaïne.)
Auteur(s) :
SHEARER J. ;
WODAK, A. ;
VAN BEEK, I. ;
MATTICK, R. P. ;
LEWIS, J.
Année
2003
Page(s) :
1137-1141
Langue(s) :
Français
Refs biblio. :
14
Domaine :
Drogues illicites / Illicit drugs
Note générale :
Addiction, 2003, 98, (8), 1137-1141
Note de contenu :
graph. ; tabl.
Résumé :
FRANÇAIS :
Trente cocaïnomanes ont été assignés au hasard soit à un traitement de 60 mg de dexamphétamines par jour, soit à un placebo pendant 14 semaines. La rétention en traitement est identique pour les 2 groupes. Le groupe recevant la dexamphétamine rapporte moins dusage de cocaïne et montre une activité criminelle moindre ainsi quune diminution du manque et de la gravité de la dépendance à la cocaïne.
ENGLISH :
Aims: To establish the feasibility of conducting a placebo-controlled clinical trial of dexamphetamine replacement therapy for cocaine dependence and to obtain preliminary data. Design: Double-blind randomized placebo-controlled trial. Participants: Thirty cocaine-dependent injecting drug users. Intervention: Subjects were assigned randomly to receive 60 mg/day dexamphetamine (n=16) or placebo (n=14) for 14 weeks. Measurements: Immunoassay and mass spectrometric techniques were used to identify cocaine metabolites in urine. Subjects were screened using the Composite International Diagnostic Interview and DSM-IV The Opiate Treatment Index, Brief Symptom Inventory, Severity of Dependence Scale and visual analogue craving scales were used to collect pre- and post-self-report data. Findings: Treatment retention was equivalent between groups: however, outcomes favoured the treatment group with no improvements observed in the placebo control group. The proportion of cocaine-positive urine samples detected in the treatment group declined from 94% to 56% compared to no change in the placebo group (79% positive). While the improvements were not significant between groups, within-group analysis revealed that the treatment group reduced self reported cocaine use (P=0.02), reduced criminal activity (P=0.04), reduced cravings (P < 0.01) and reduced severity of cocaine dependence (P < 0.0l) with no within-group improvements found in the placebo group. Conclusions: A definitive evaluation of the utility of dexamphetamine in the management of cocaine dependence is feasible and warranted. (Author' s abstract)
Trente cocaïnomanes ont été assignés au hasard soit à un traitement de 60 mg de dexamphétamines par jour, soit à un placebo pendant 14 semaines. La rétention en traitement est identique pour les 2 groupes. Le groupe recevant la dexamphétamine rapporte moins dusage de cocaïne et montre une activité criminelle moindre ainsi quune diminution du manque et de la gravité de la dépendance à la cocaïne.
ENGLISH :
Aims: To establish the feasibility of conducting a placebo-controlled clinical trial of dexamphetamine replacement therapy for cocaine dependence and to obtain preliminary data. Design: Double-blind randomized placebo-controlled trial. Participants: Thirty cocaine-dependent injecting drug users. Intervention: Subjects were assigned randomly to receive 60 mg/day dexamphetamine (n=16) or placebo (n=14) for 14 weeks. Measurements: Immunoassay and mass spectrometric techniques were used to identify cocaine metabolites in urine. Subjects were screened using the Composite International Diagnostic Interview and DSM-IV The Opiate Treatment Index, Brief Symptom Inventory, Severity of Dependence Scale and visual analogue craving scales were used to collect pre- and post-self-report data. Findings: Treatment retention was equivalent between groups: however, outcomes favoured the treatment group with no improvements observed in the placebo control group. The proportion of cocaine-positive urine samples detected in the treatment group declined from 94% to 56% compared to no change in the placebo group (79% positive). While the improvements were not significant between groups, within-group analysis revealed that the treatment group reduced self reported cocaine use (P=0.02), reduced criminal activity (P=0.04), reduced cravings (P < 0.01) and reduced severity of cocaine dependence (P < 0.0l) with no within-group improvements found in the placebo group. Conclusions: A definitive evaluation of the utility of dexamphetamine in the management of cocaine dependence is feasible and warranted. (Author' s abstract)
Affiliation :
National Drug and Alcohol Research Centre, Univ. of New South Wales, Sydney, NSW 2052. Email : j.shearerunsw.edu.au
Australie. Australia.
Australie. Australia.
Cote :
A01902